CeriBell (NASDAQ:CBLL) CTO Sells $147,587.75 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 8,087 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $18.25, for a total value of $147,587.75. Following the completion of the sale, the chief technology officer owned 166,912 shares in the company, valued at $3,046,144. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Raymond Woo also recently made the following trade(s):

• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total transaction of $13,951.95.
• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total transaction of $235,352.16.

CeriBell Stock Performance

NASDAQ CBLL traded up $0.25 on Wednesday, hitting $17.79. The stock had a trading volume of 61,083 shares, compared to its average volume of 346,915. The company’s 50-day moving average is $20.98 and its two-hundred day moving average is $16.40. CeriBell, Inc. has a one year low of $10.01 and a one year high of $24.33. The stock has a market cap of $669.62 million, a price-to-earnings ratio of -12.10 and a beta of 1.12. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The business had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Large investors have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in shares of CeriBell during the second quarter valued at $1,054,000. Geode Capital Management LLC raised its holdings in CeriBell by 55.4% during the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after buying an additional 159,698 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in CeriBell by 58.2% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after buying an additional 57,175 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares during the period. Finally, F m Investments LLC purchased a new position in shares of CeriBell in the second quarter worth approximately $381,000.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of recent analyst reports. BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. JPMorgan Chase & Co. lowered their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Canaccord Genuity Group boosted their target price on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.